617 Patients with lung cancer were screened from 19 centers

Excluded (n = 59)

- Previous use of third-generation EGFR-TKI (n=21)
- Inadequate for medical records for review (n=18)
- Previous enrollment in other clinical trials (n=14)
- Osimertinib used as first-line chemotherapy (n=3)
- Combined other malignancies (n=2)
- No previous use of EGFR-TKI (n=1)

558 eligible patients were enrolled for data analysis

S1 Fig. Study flowchart. EGFR-TKI, epidermal growth factor receptor tyrosine kinase inhibitor.